Clinical predictors of chimeric antigen receptor T-cell therapy neurotoxicity: a single-center study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34558978/
Aims: Neurotoxicity (NT) is a common complication of chimeric antigen receptor (CAR) T-cell therapy. Data on early clinical identifiers for impending severe NT are lacking. Methods: The authors performed a...
Conclusion: In the authors' limited cohort, the dysgraphia, disorientation and inattention components of the CAR T-cell therapy-associated toxicity 10 scoring system were significantly associated with and predictive of impending severe NT.
CAR T-cell Therapy for Secondary CNS DLBCL - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34551065/
Management of secondary central nervous system involvement (SCNSL) in relapsed or refractory aggressive B-cell lymphomas remains an area of unmet medical need. We report a single center retrospective analysis of...
CTLA-4 promotes lymphoma progression through tumor stem cell enrichment and immunosuppression - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34553071/
The recurrence rate of lymphoma is very high, and tumor stem cells may be an important mechanism. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can inhibit antitumor immunity and promote cancer...
Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34557402/
The clinical and molecular characteristics of localized diffuse large B-cell lymphoma (DLBCL) with single nodal (SN) or single extranodal (SE) involvement remain largely elusive in the rituximab era. The clinical...
Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34521813/
The ability of patients with hematologic malignancies (HM) to develop an effective humoral immune response after COVID-19 is unknown. A prospective study was performed to monitor the immune response to...